Arcus Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcus Biosciences (RCUS).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

11Buy

1Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$36Upside to Avg. PT+46.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$43
Sep 16, 2026	TD Cowen	Tara Bancroft	Initiate	Buy	—
Sep 8, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$35→$40
Aug 6, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$23→$26
Aug 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$41→$43
Jul 20, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$32→$45
Jun 4, 2026	LifeSci Capital	Charles Zhu	Initiate	Outperform	$46
May 18, 2026	Truist Securities	Supawat Thongthip	Assumes	Buy	$30→$35
May 11, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$20→$22
May 7, 2026	Goldman Sachs	Richard Law	PT Raise	Buy	$30→$34
Apr 2, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$37→$41
Mar 5, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$44→$45
Mar 2, 2026	Leerink Partners	Geoffrey Porges	PT Raise	Outperform	$36→$49
Mar 2, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$32
Feb 12, 2026	Wells Fargo	Eva Fortea Verdejo	Downgrade	Overweight→Equal-Weight	$30→$23
Jan 13, 2026	Goldman Sachs	Richard Law	Upgrade	Neutral→Buy	$16→$28
Jan 8, 2026	Morgan Stanley	Terence Flynn	Downgrade	Overweight→Equal-Weight	$23→$20
Dec 12, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$28→$32
Nov 28, 2025	B of A Securities	Jason Zemansky	PT Raise	Neutral	$17→$26
Oct 30, 2025	Goldman Sachs	Salveen Richter	PT Raise	Neutral	$14→$16

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $43 price target.

Benzinga Newsdesk

PRO
TD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating

TD Cowen analyst Tara Bancroft initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Buy rating.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

Truist Securities analyst Supawat Thongthip reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $35 to $40.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.

Benzinga Newsdesk

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casdatifan in first-line ccRCC.

Vandana Singh

Arcus Biosciences Inc

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

PRO
TD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating

PRO
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

PRO
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

People Also Watch

People Also Watch

Arcus Biosciences Inc

Arcus Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

PROTD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating

PROTruist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

PROWells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

PROWedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

People Also Watch

People Also Watch

PRO
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

PRO
TD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating

PRO
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

PRO
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43